Intermittent Dosing Of Rmc-4630, A Potent, Selective Inhibitor Of Shp2, Combined With The Mek Inhibitor Cobimetinib, In A Phase 1b/2 Clinical Trial For Advanced Solid Tumors With Activating Mutations Of Ras Signaling

EUROPEAN JOURNAL OF CANCER(2020)

引用 12|浏览45
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要